U.S. UTERINE FIBROID TREATMENT MARKET ANALYSIS

U.S. Uterine Fibroid Treatment Market, By Procedure Type (Endometrial Ablation, MRI Guided Procedures (MRI-guided Percutaneous Laser Ablation, and MRI-guided Transcutaneous Focused Ultrasound), Hysterectomy (Abdominal Hysterectomy, Vaginal Hysterectomy, Laparoscopic Hysterectomy, Robotic Hysterectomy, and Hysteroscopic Morcellation), Myomectomy (Open Myomectomy, Laparoscopic Myomectomy, and Robotic Myomectomy), Uterine Artery Embolization, Radiofrequency Ablation, and Others) and By End User (Hospitals and Ambulatory Surgical Centers)-

Published In : Jun 2023
Code : CMI3866
Pages :166
Formats :
Excel and PDF
Industry : Medical Devices

Market News

U.S Uterine Fibroids Treatment Market: Key Developments

Major players in the market are focused on R&D to expand their product portfolio. For instance, in April 2020, Sumitovant Biopharma Ltd., a technology-driven biopharma announced publication of abstracts from Myovant Sciences regarding the efficacy and safety of relugolix combination therapy in women with heavy menstrual bleeding associated with uterine fibroids, in the journal Obstetrics & Gynecology.

In June 2021, Hologic, Inc., a medical technology company, primarily focused on women’s health; it sells medical devices for diagnostics, surgery, and medical imaging, announced that Cigna, a multinational managed healthcare and insurance company, has updated its medical policy to cover the Acessa Laparoscopic Radiofrequency Ablation (Lap-RFA) procedure (CPT code 58674) as medically necessary.

In January 2022, Hologic, Inc. a medical technology company, primarily focused on women’s health; it sells medical devices for diagnostics, surgery, and medical imaging announced, the launch of Hey, U!, an educational campaign focused on uterine health due to a lack of awareness among U.S. women about uterine health, including uterine fibroid symptoms and treatment options.

In November 2022, Olympus Corporation, a global technology in designing and delivering innovative solutions for medical and surgical procedures, announced the market launch of the moresolution Power Morcellator, which is manufactured by TROKAMED GmbH and is available in the U.S. through a distribution agreement with Olympus America, Inc. The moresolution Morcellator is designed for advanced gynecologic procedures with large, calcified tissue specimens.